Developer docs
API playgroundTry for free, no card

Search company profiles

BrainXell

Full company profile

uuid00021bf

Namestring
BrainXell
Legal namestring
BrainXell, Inc.
Websiteurl
brainxell.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

BrainXell is a Madison, Wisconsin-based biotechnology company founded in 2015 by Dr. Su-Chun Zhang, a pioneer in stem-cell-derived neural cell technology. The company manufactures iPSC-derived human neural cell products — including motor, cortical glutamatergic and GABAergic, midbrain dopaminergic, medium spiny, and sensory neurons, plus astrocytes, microglia, oligodendrocyte progenitor cells, endothelial cells, disease-specific lines, and reporter cell lines — for pharmaceutical drug-discovery and academic neuroscience research. Its 50+ product catalog is supported by 50+ scientific publications and 50+ poster validations, and the company reports its cells are used by 75%+ of the world's largest pharmaceutical companies alongside academic customers.

The company monetizes through direct catalog sales of cryopreserved and live cell products priced between $25 and $3,055 per unit, supplemented by higher-value service offerings including custom iPSC differentiation, iPSC reprogramming, and assay services, plus the BrainBloX neuromuscular asset platform and BrainFast cell-culture supplements. Distribution combines direct North American sales with a global network of distributors covering Japan (Funakoshi), Europe, and additional Asia-Pacific markets. In addition to research tools, BrainXell has begun a therapeutic push with BXT-110, an iPSC-derived dopaminergic neuron candidate for Parkinson's disease currently in preclinical development, and has formed partnerships with EditCo/Synthego for gene-edited iPSC lines and NeuroDex for exosome applications.

BrainXell has raised $13.25M in a 2021 SEC Form D filing, operates with 11-50 employees, and serves both enterprise pharma and academic end-markets. Customer diversification spans large pharma, biotech firms such as Neurona, and academic institutions, with custom service contracts representing the higher-value revenue tier alongside catalog unit sales.

Short descriptiontext

BrainXell manufactures iPSC-derived human neural cell products — including neurons, astrocytes, microglia, OPCs, and disease-specific lines — for pharmaceutical drug discovery and academic neuroscience research, distributing globally and pursuing cell-therapy applications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMadison, United States
HQ citystring
Madison
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
iPSC-derived neurons, neural cell products, drug discovery cells, stem cell services, neuroscience research tools
Industry2 codes
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
iPSC-Derived Neural Cells
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1iPSC-Derived Cell Products
TypeOne Time License
Description

Sale of cryopreserved human iPSC-derived neurons, astrocytes, microglia, endothelial cells, OPCs, and related supplements. Products are sold in various vial sizes (1M, 2M/2.5M, 5M cells) with pricing ranging from $25 for supplements to $3,055 for specialized microglia variants. Revenue is one-time per transaction with repeat purchases for ongoing research.

brainxell.com
2Custom Differentiation Services
TypeProfessional Services
Description

Custom production of neural and glial cells from client-provided iPSC lines, accommodating scales from 25 million to 20 billion cells. BrainXell dedicates over half of its production capacity to custom differentiation projects. Projects are flexible with varying characterization needs and delivery formats.

brainxell.com
3iPSC Reprogramming Services
TypeProfessional Services
Description

Fee-for-service reprogramming of human fibroblasts into iPSCs using advanced mRNA technology. Typical turnaround of 3 months from fibroblast receipt to iPSC delivery. Provides both clonal and pooled iPSC lines with COA and characterization documentation.

brainxell.com
4Assay Services
TypeProfessional Services
Description

Small-scale assay services including toxicity/viability assays, immunofluorescence and microscopy, multi-electrode array (MEA) assays, qPCR gene expression analysis, and neuronal culture with drug treatments. Performed using BrainXell iPSC-derived cells in 96-well format.

brainxell.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details8 tiers
1Standard Neuron Products (1M-5M cells)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Cortical GABAergic, Cortical Glutamatergic, Spinal Motor, Sensory, Medium Spiny neurons: 1M vial $650, 2M/2.5M vial $1,060-$1,275, 5M vial $1,750-$2,100. Midbrain Dopaminergic neurons: similar tiered pricing with 1M at $650.

brainxell.com
2Specialty Cell Products with Reporters/Edits
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Reporter cells (eGFP, GCaMP8f/m, RCaMP1a) add $65-$130 premium: $715-$780 (1M), $1,020-$1,275 (2M), $1,925-$2,100 (5M). Disease-edited cells (APOE4/E4, TREM2 variants): $750-$1,295 (1M), $1,225-$1,735 (2M), $2,015-$3,055 (5M).

brainxell.com
3Astrocyte Products
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Cortical Astrocytes: 1M $925, 2M $1,300-$1,495, 5M $2,425-$2,790. Spinal Astrocytes: 1M $925, 5M $2,425. APOE4/E4 variant adds $140 premium.

brainxell.com
4Microglia Products
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Standard microglia: 1M $1,175, 2M $1,575, 5M $2,775. eGFP reporter: $1,235/$1,655/$2,915. Disease variants (APOE4/E4, TREM2 KO/R47H/R62H/D87N): $1,295/$1,735/$3,055.

brainxell.com
5Endothelial Cells
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Standard: 1M $1,175, 2M $1,575, 5M $2,775. eGFP reporter: $1,235/$1,655/$2,915.

brainxell.com
6BrainFast Supplements
ModelUnit PricingBilling cadencePay-as-you-go
Notes

All BrainFast variants (Astro, D4, Dopa, GABA, Glut, Motor, SK): 100µL $25, 1mL $100. Sold in packs sufficient for 15+ multi-well plates.

brainxell.com
7Oligodendrocyte Progenitor Cells (OPCs)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

BX-1300 OPCs: 1M $925, 2M $1,300, 5M $2,425.

brainxell.com
8Custom Differentiation Services
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based pricing. Scale ranges from 25 million to 20 billion cells. Accommodates human iPSCs, ESCs, primate iPSCs/ESCs, and human fibroblasts. Timeline typically 4-6 months for up to half a billion differentiated neurons.

brainxell.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1BrainBloX
Description

BrainBloX is BrainXell's modular framework for designing human-relevant CNS systems tailored to specific research questions. Starting with a foundation of human iPSC-derived neurons, astrocytes, microglia, oligodendrocytes, disease-specific lines, and reporter technologies, researchers can select the cellular components most relevant to their biology and combine them into customized experimental platforms.

brainxell.com
+2 more records
Core offering1 text field

BrainXell manufactures and sells high-purity, cryopreserved human induced pluripotent stem cell (iPSC)-derived neurons, astrocytes, microglia, endothelial cells, and oligodendrocyte progenitor cells for neuroscience research and drug discovery. The company also offers custom differentiation services (scales from 25 million to 20 billion cells), mRNA-based iPSC reprogramming services, and small-scale assay services (MEA, qPCR, immunofluorescence, toxicity), complemented by BrainFast maturation supplements and BrainBloX modular CNS model systems.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Greater than 90% neuronal purity across neuron products
+3 more records
Product overview1 text field

BrainXell is a biotechnology company offering a comprehensive portfolio of human iPSC-derived neural and glial cells for neuroscience research and drug discovery. The core product line includes neurons (Spinal Motor Neurons, Cortical Glutamatergic Neurons, Cortical GABAergic Neurons, Medium Spiny GABAergic Neurons, Midbrain Dopaminergic Neurons, Sensory Neurons, Mixed Cortical Neurons), astrocytes (Cortical Astrocytes, Spinal Astrocytes), Microglia, Endothelial Cells, and Oligodendrocyte Progenitor Cells (OPCs). Disease-specific variants and Reporter Cell lines (eGFP, GCaMP8f/m, RCaMP1a) enable targeted research applications. The BrainFast supplement line accelerates neuronal maturation. Services include Custom Differentiation (scale from 25M to 20B cells), iPSC Reprogramming (mRNA-based, 3-month turnaround), and Assay Services (toxicity, MEA, qPCR, immunofluorescence). The BrainBloX NAM Platform provides modular CNS model systems combining multiple cell types for 2D/3D culture applications.

Product and service19 records
1Spinal Motor Neurons
CategoryCore product - Neurons
Description

Cryopreserved human iPSC-derived spinal motor neurons with greater than 90% purity and greater than 70% motor neuron content, expressing MAP2 and FOXP1 markers. Suitable for neurodegenerative disease research, drug discovery, and neurotoxicity screening.

2Cortical Glutamatergic Neurons
CategoryCore product - Neurons
Description

Cryopreserved human iPSC-derived excitatory cortical neurons with greater than 90% purity, expressing CTIP2 and TBR1 markers. Used for neuroscience research, synaptic biology, and cortical disease modeling.

3Cortical GABAergic Neurons
CategoryCore product - Neurons
Description

Cryopreserved human iPSC-derived inhibitory neurons with greater than 90% purity expressing GABA. Used for studying inhibitory signaling, epilepsy research, and cortical network studies.

4Medium Spiny GABAergic Neurons
CategoryCore product - Neurons
Description

Human iPSC-derived medium spiny neurons for Huntington's disease research and striatal neural circuit studies.

5Midbrain Dopaminergic Neurons
CategoryCore product - Neurons
Description

Human iPSC-derived midbrain dopaminergic neurons containing 50% TH+ cells for Parkinson's disease research and dopaminergic signaling studies.

6Human iPSC-Derived Sensory Neurons
CategoryCore product - Neurons
Description

Human iPSC-derived peripheral sensory neurons expressing Nav1.7-1.9 channels, TRPV1, TRPM8, P2RX3, and opioid receptors. Designed for pain biology, sensory transduction, and ion channel pharmacology research.

7Mixed Cortical Neurons
CategoryCore product - Neurons
Description

Kit combining cortical glutamatergic and GABAergic neurons at a 5:1 ratio for studying excitatory/inhibitory balance and cortical circuit function.

8Cortical Astrocytes
CategoryCore product - Astrocytes
Description

Cryopreserved human iPSC-derived cortical astrocytes expressing GFAP and S100B at greater than 90%, capable of glutamate uptake. Used for neuroimmune studies and co-culture systems.

9Spinal Astrocytes
CategoryCore product - Astrocytes
Description

Human iPSC-derived spinal astrocytes with greater than 90% expressing GFAP, ALDH1L1, and Vimentin. Ready for functional assays 7 days post-thaw.

10Microglia
CategoryCore product - Microglia
Description

Cryopreserved human iPSC-derived microglia demonstrating phagocytosis and cytokine secretion. Available in wild-type, reporter, and disease variants including APOE4/E4 and TREM2 mutations.

11Endothelial Cells
CategoryCore product - Endothelial Cells
Description

Human iPSC-derived brain endothelial cells with greater than 95% VE-Cadherin+ expression for blood-brain barrier research and neurovascular modeling.

12Oligodendrocyte Progenitor Cells (OPCs)
CategoryCore product - OPCs
Description

Human iPSC-derived OPCs expressing O4, SOX10, and MBP for studying oligodendrocyte maturation, myelination, and myelinoid applications.

13Disease Cells
CategoryCore product - Disease Cells
Description

Disease-specific iPSC-derived cells including APOE4/E4 edits, TREM2 KO, TREM2 R47H, and patient-derived SOD1 mutations for Alzheimer's, Parkinson's, and ALS research.

14Reporter Cells
CategoryCore product - Reporter Cells
Description

iPSC-derived neurons and glia with functional reporters including eGFP, GCaMP8f, GCaMP8m, and RCaMP1a for real-time visualization of cellular activity and signaling.

15BrainFast Supplements
CategoryReagent - Supplements
Description

Proprietary small molecule supplements (BrainFast Motor, Glut, GABA, Dopa, Astro, D4, SK) for accelerated neural progenitor maturation to mature neurons in 1-2 weeks.

16Custom Differentiation Services
CategoryService - Custom Production
Description

Fee-for-service custom differentiation of client-provided iPSCs into specific neural and glial cell types at scales from 25 million to 20 billion cells. Includes disease, isogenic corrected, gene-edited, and reporter lines. BrainXell dedicates over half of its production capacity to these custom projects.

17iPSC Reprogramming Services
CategoryService - Custom Production
Description

Footprint-free, xeno-free reprogramming of patient fibroblasts to iPSCs using advanced mRNA technology with 3-month turnaround. Delivers clonal and pooled iPSC lines with COA and STR analysis.

18Assay Services
CategoryService - Assay Services
Description

Small-scale assay services including toxicity/viability assays, immunofluorescence/microscopy, multi-electrode array (MEA) assays, qPCR gene expression analysis, and neuronal culture with drug treatments. Performed using BrainXell iPSC-derived cells in 96-well format.

19BXT-110 Autologous iPSC-Derived Neuronal Therapy for Parkinson's Disease
CategoryPipeline - Cell Therapy
Description

Autologous iPSC-derived midbrain dopaminergic progenitor therapy candidate for Parkinson's disease, demonstrating significant graft survival and functional recovery in preclinical rodent models.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

As part of the Edit Co (Synthego) Discovery Partnership Ecosystem, BrainXell control iPSC lines are fast-tracked for rapid turnaround of iPSC editing projects, enabling streamlined workflows from gene editing to differentiated neural cells.

Strategic tierSupportingTypeTechnology or Integration
Description

Collaboration with NeuroDex, which developed proprietary neuron-derived exosome isolation technology. BrainXell confirmed exosome secretion from iPSC-derived cortical neurons, enabling applications in diagnostics, therapeutics, and research.

Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Regional distributor for Belgium, Netherlands, and Luxembourg. Contact: +31 (0)26-326-4450, info@bio-connect.nl, orders@bio-connect.nl

Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Regional distributor for United Kingdom. Contact: +44 (0) 1638 782600, info@stratech.co.uk, orders@stratech.co.uk

Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Regional distributor for Germany, Austria, and Switzerland. Contact: +49 (089) 3799 666-6, bestellung@biozol.de, info@biozol.de

Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Regional distributor for France and Italy. Contact: +39 06 94 80 56 71, info@clinisciences.com, italia@clinisciences.com

7Quimigen
Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Regional distributor for Spain. Contact: +34 91 675 0700, pedidos@quimigen.com

brainxell.com
8Funakoshi Co., Ltd.
Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Regional distributor for Japan. Contact: +81 3 5684 1620, reagent@funakoshi.co.jp

brainxell.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specializes in iPSC-derived neural cells and 3D brain models for CNS drug discovery and toxicity testing. Closely comparable focus on human neural in vitro models for pharma.

TypeDirect peer
Description

Largest commercial supplier of human iPSC-derived cells, including neurons, for drug discovery and research. Direct competitor across BrainXell's core catalog product lines, with significantly greater scale and a broader portfolio.

TypeDirect peer
Description

Develops iPSC-derived cell products and assay services for cardiac and neural drug discovery. Closely comparable in business model (catalog cells + custom services + assay support) and customer base (pharma and biotech).

TypeDirect peer
Description

Precision reprogramming company producing human iPSC-derived cell types at scale, including neural cells for research and drug discovery. Comparable technology platform and pharma customer overlap.

TypeDirect peer
Description

Supplier of iPSC-derived neural and other cell types plus custom services for neuroscience and drug discovery research. Direct competitor in iPSC-derived neural cell products.

TypeDirect peer
Description

Develops autologous iPSC-derived dopaminergic neuron cell therapies for Parkinson's disease. Direct peer to BrainXell's BXT-110 program, using overlapping iPSC-to-dopaminergic-neuron differentiation IP.

TypeDirect peer
Description

Provides iPSC-derived cell products and stem cell-related services for drug discovery and regenerative medicine. Comparable catalog-plus-services model in human iPSC reagents.

TypeBroad incumbent
Description

Major life sciences tools supplier of stem cell culture reagents, media, and primary cell products. Overlaps with BrainXell via shared stem cell and neural cell research customer base, though STEMCELL has a much broader, less specialized portfolio.

TypeBroad incumbent
Description

Diversified life sciences tools giant whose bioscience offerings (including Gibco media and cell culture reagents) compete for the same pharma and academic neuroscience budgets. Not a direct neural-cell competitor but competes for tooling wallet.

TypeEmerging player
Description

Provider of primary cells, iPSC-derived cells, and custom cell services for drug discovery. Smaller, emerging competitor with overlapping custom services and disease-model offerings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BrainXell

iPSC-Derived Neural Cellsbrainxell.com

BrainXell manufactures iPSC-derived human neural cell products — including neurons, astrocytes, microglia, OPCs, and disease-specific lines — for pharmaceutical drug discovery and academic neuroscience research, distributing globally and pursuing cell-therapy applications.

What BrainXell does

BrainXell is a Madison, Wisconsin-based biotechnology company founded in 2015 by Dr. Su-Chun Zhang, a pioneer in stem-cell-derived neural cell technology. The company manufactures iPSC-derived human neural cell products — including motor, cortical glutamatergic and GABAergic, midbrain dopaminergic, medium spiny, and sensory neurons, plus astrocytes, microglia, oligodendrocyte progenitor cells, endothelial cells, disease-specific lines, and reporter cell lines — for pharmaceutical drug-discovery and academic neuroscience research. Its 50+ product catalog is supported by 50+ scientific publications and 50+ poster validations, and the company reports its cells are used by 75%+ of the world's largest pharmaceutical companies alongside academic customers.

The company monetizes through direct catalog sales of cryopreserved and live cell products priced between $25 and $3,055 per unit, supplemented by higher-value service offerings including custom iPSC differentiation, iPSC reprogramming, and assay services, plus the BrainBloX neuromuscular asset platform and BrainFast cell-culture supplements. Distribution combines direct North American sales with a global network of distributors covering Japan (Funakoshi), Europe, and additional Asia-Pacific markets. In addition to research tools, BrainXell has begun a therapeutic push with BXT-110, an iPSC-derived dopaminergic neuron candidate for Parkinson's disease currently in preclinical development, and has formed partnerships with EditCo/Synthego for gene-edited iPSC lines and NeuroDex for exosome applications.

BrainXell has raised $13.25M in a 2021 SEC Form D filing, operates with 11-50 employees, and serves both enterprise pharma and academic end-markets. Customer diversification spans large pharma, biotech firms such as Neurona, and academic institutions, with custom service contracts representing the higher-value revenue tier alongside catalog unit sales.

BrainXell firmographics

Firmographics
Name
BrainXell
Legal name
BrainXell, Inc.
Website
https://brainxell.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
BrainXell manufactures iPSC-derived human neural cell products — including neurons, astrocytes, microglia, OPCs, and disease-specific lines — for pharmaceutical drug discovery and academic neuroscience research, distributing globally and pursuing cell-therapy applications.
Ownership category
akta.pro rank

BrainXell industry classification

Industry
Product category
iPSC-Derived Neural Cells
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • IPSC-derived neurons
  • Neural cell products
  • Drug discovery cells
  • Stem cell services
  • Neuroscience research tools

Where BrainXell is headquartered

Location

Headquarters

HQ city
Madison
HQ country
United States
HQ region
North America

Offices1 record

Markets served

BrainXell business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. iPSC-Derived Cell Products: Sale of cryopreserved human iPSC-derived neurons, astrocytes, microglia, endothelial cells, OPCs, and related supplements. Products are sold in various vial sizes (1M, 2M/2.5M, 5M cells) with pricing ranging from $25 for supplements to $3,055 for specialized microglia variants. Revenue is one-time per transaction with repeat purchases for ongoing research.
  2. Custom Differentiation Services: Custom production of neural and glial cells from client-provided iPSC lines, accommodating scales from 25 million to 20 billion cells. BrainXell dedicates over half of its production capacity to custom differentiation projects. Projects are flexible with varying characterization needs and delivery formats.
  3. iPSC Reprogramming Services: Fee-for-service reprogramming of human fibroblasts into iPSCs using advanced mRNA technology. Typical turnaround of 3 months from fibroblast receipt to iPSC delivery. Provides both clonal and pooled iPSC lines with COA and characterization documentation.
  4. Assay Services: Small-scale assay services including toxicity/viability assays, immunofluorescence and microscopy, multi-electrode array (MEA) assays, qPCR gene expression analysis, and neuronal culture with drug treatments. Performed using BrainXell iPSC-derived cells in 96-well format.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goStandard Neuron Products (1M-5M cells)
Unit PricingPay-as-you-goSpecialty Cell Products with Reporters/Edits
Unit PricingPay-as-you-goAstrocyte Products
Unit PricingPay-as-you-goMicroglia Products
Unit PricingPay-as-you-goEndothelial Cells
Unit PricingPay-as-you-goBrainFast Supplements
Unit PricingPay-as-you-goOligodendrocyte Progenitor Cells (OPCs)
OtherMulti-year contractCustom Differentiation Services

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

BrainXell product offering

Product offering

Core offering

BrainXell manufactures and sells high-purity, cryopreserved human induced pluripotent stem cell (iPSC)-derived neurons, astrocytes, microglia, endothelial cells, and oligodendrocyte progenitor cells for neuroscience research and drug discovery. The company also offers custom differentiation services (scales from 25 million to 20 billion cells), mRNA-based iPSC reprogramming services, and small-scale assay services (MEA, qPCR, immunofluorescence, toxicity), complemented by BrainFast maturation supplements and BrainBloX modular CNS model systems.

Product overview

BrainXell is a biotechnology company offering a comprehensive portfolio of human iPSC-derived neural and glial cells for neuroscience research and drug discovery. The core product line includes neurons (Spinal Motor Neurons, Cortical Glutamatergic Neurons, Cortical GABAergic Neurons, Medium Spiny GABAergic Neurons, Midbrain Dopaminergic Neurons, Sensory Neurons, Mixed Cortical Neurons), astrocytes (Cortical Astrocytes, Spinal Astrocytes), Microglia, Endothelial Cells, and Oligodendrocyte Progenitor Cells (OPCs). Disease-specific variants and Reporter Cell lines (eGFP, GCaMP8f/m, RCaMP1a) enable targeted research applications. The BrainFast supplement line accelerates neuronal maturation. Services include Custom Differentiation (scale from 25M to 20B cells), iPSC Reprogramming (mRNA-based, 3-month turnaround), and Assay Services (toxicity, MEA, qPCR, immunofluorescence). The BrainBloX NAM Platform provides modular CNS model systems combining multiple cell types for 2D/3D culture applications.

Differentiator

Problem solved

Functional benefit

Brands

  • BrainBloX: BrainBloX is BrainXell's modular framework for designing human-relevant CNS systems tailored to specific research questions. Starting with a foundation of human iPSC-derived neurons, astrocytes, microglia, oligodendrocytes, disease-specific lines, and reporter technologies, researchers can select the cellular components most relevant to their biology and combine them into customized experimental platforms.
  • BrainFast
  • NAMs (New Approach Methodologies)

Products and services

  • Spinal Motor Neurons Cryopreserved human iPSC-derived spinal motor neurons with greater than 90% purity and greater than 70% motor neuron content, expressing MAP2 and FOXP1 markers. Suitable for neurodegenerative disease research, drug discovery, and neurotoxicity screening.
  • Cortical Glutamatergic Neurons Cryopreserved human iPSC-derived excitatory cortical neurons with greater than 90% purity, expressing CTIP2 and TBR1 markers. Used for neuroscience research, synaptic biology, and cortical disease modeling.
  • Cortical GABAergic Neurons Cryopreserved human iPSC-derived inhibitory neurons with greater than 90% purity expressing GABA. Used for studying inhibitory signaling, epilepsy research, and cortical network studies.
  • Medium Spiny GABAergic Neurons Human iPSC-derived medium spiny neurons for Huntington's disease research and striatal neural circuit studies.
  • Midbrain Dopaminergic Neurons Human iPSC-derived midbrain dopaminergic neurons containing 50% TH+ cells for Parkinson's disease research and dopaminergic signaling studies.
  • Human iPSC-Derived Sensory Neurons Human iPSC-derived peripheral sensory neurons expressing Nav1.7-1.9 channels, TRPV1, TRPM8, P2RX3, and opioid receptors. Designed for pain biology, sensory transduction, and ion channel pharmacology research.
  • Mixed Cortical Neurons Kit combining cortical glutamatergic and GABAergic neurons at a 5:1 ratio for studying excitatory/inhibitory balance and cortical circuit function.
  • Cortical Astrocytes Cryopreserved human iPSC-derived cortical astrocytes expressing GFAP and S100B at greater than 90%, capable of glutamate uptake. Used for neuroimmune studies and co-culture systems.
  • Spinal Astrocytes Human iPSC-derived spinal astrocytes with greater than 90% expressing GFAP, ALDH1L1, and Vimentin. Ready for functional assays 7 days post-thaw.
  • Microglia Cryopreserved human iPSC-derived microglia demonstrating phagocytosis and cytokine secretion. Available in wild-type, reporter, and disease variants including APOE4/E4 and TREM2 mutations.
  • Endothelial Cells Human iPSC-derived brain endothelial cells with greater than 95% VE-Cadherin+ expression for blood-brain barrier research and neurovascular modeling.
  • Oligodendrocyte Progenitor Cells (OPCs) Human iPSC-derived OPCs expressing O4, SOX10, and MBP for studying oligodendrocyte maturation, myelination, and myelinoid applications.
  • Disease Cells Disease-specific iPSC-derived cells including APOE4/E4 edits, TREM2 KO, TREM2 R47H, and patient-derived SOD1 mutations for Alzheimer's, Parkinson's, and ALS research.
  • Reporter Cells iPSC-derived neurons and glia with functional reporters including eGFP, GCaMP8f, GCaMP8m, and RCaMP1a for real-time visualization of cellular activity and signaling.
  • BrainFast Supplements Proprietary small molecule supplements (BrainFast Motor, Glut, GABA, Dopa, Astro, D4, SK) for accelerated neural progenitor maturation to mature neurons in 1-2 weeks.
  • Custom Differentiation Services Fee-for-service custom differentiation of client-provided iPSCs into specific neural and glial cell types at scales from 25 million to 20 billion cells. Includes disease, isogenic corrected, gene-edited, and reporter lines. BrainXell dedicates over half of its production capacity to these custom projects.
  • iPSC Reprogramming Services Footprint-free, xeno-free reprogramming of patient fibroblasts to iPSCs using advanced mRNA technology with 3-month turnaround. Delivers clonal and pooled iPSC lines with COA and STR analysis.
  • Assay Services Small-scale assay services including toxicity/viability assays, immunofluorescence/microscopy, multi-electrode array (MEA) assays, qPCR gene expression analysis, and neuronal culture with drug treatments. Performed using BrainXell iPSC-derived cells in 96-well format.
  • BXT-110 Autologous iPSC-Derived Neuronal Therapy for Parkinson's Disease Autologous iPSC-derived midbrain dopaminergic progenitor therapy candidate for Parkinson's disease, demonstrating significant graft survival and functional recovery in preclinical rodent models.

Quantifiable outcome

  • Greater than 90% neuronal purity across neuron products
  • +3 more outcomes

Companies that use BrainXell

Customer profile

Named customers8 records

Segments3 records

Ideal customer profiles3 records

BrainXell technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

Feature5 records

BrainXell partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and supporting.

  • Edit Co (Synthego)coreStrategic or Co-development PartnerAs part of the Edit Co (Synthego) Discovery Partnership Ecosystem, BrainXell control iPSC lines are fast-tracked for rapid turnaround of iPSC editing projects, enabling streamlined workflows from gene editing to differentiated neural cells.
  • NeuroDexsupportingTechnology or IntegrationCollaboration with NeuroDex, which developed proprietary neuron-derived exosome isolation technology. BrainXell confirmed exosome secretion from iPSC-derived cortical neurons, enabling applications in diagnostics, therapeutics, and research.
  • Bio-Connect B.V.supportingChannel Partner/ Reseller/ DistributorRegional distributor for Belgium, Netherlands, and Luxembourg. Contact: +31 (0)26-326-4450, info@bio-connect.nl, orders@bio-connect.nl
  • StratechsupportingChannel Partner/ Reseller/ DistributorRegional distributor for United Kingdom. Contact: +44 (0) 1638 782600, info@stratech.co.uk, orders@stratech.co.uk
  • BIOZOL Diagnostica Vertrieb GmbHsupportingChannel Partner/ Reseller/ DistributorRegional distributor for Germany, Austria, and Switzerland. Contact: +49 (089) 3799 666-6, bestellung@biozol.de, info@biozol.de
  • CliniSciencessupportingChannel Partner/ Reseller/ DistributorRegional distributor for France and Italy. Contact: +39 06 94 80 56 71, info@clinisciences.com, italia@clinisciences.com
  • QuimigensupportingChannel Partner/ Reseller/ DistributorRegional distributor for Spain. Contact: +34 91 675 0700, pedidos@quimigen.com
  • Funakoshi Co., Ltd.supportingChannel Partner/ Reseller/ DistributorRegional distributor for Japan. Contact: +81 3 5684 1620, reagent@funakoshi.co.jp

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

BrainXell competitors and assessment

Company assessment

Direct peers

  • NeuCyte: Specializes in iPSC-derived neural cells and 3D brain models for CNS drug discovery and toxicity testing. Closely comparable focus on human neural in vitro models for pharma.
  • FUJIFILM Cellular Dynamics: Largest commercial supplier of human iPSC-derived cells, including neurons, for drug discovery and research. Direct competitor across BrainXell's core catalog product lines, with significantly greater scale and a broader portfolio.
  • Ncardia: Develops iPSC-derived cell products and assay services for cardiac and neural drug discovery. Closely comparable in business model (catalog cells + custom services + assay support) and customer base (pharma and biotech).
  • bit.bio: Precision reprogramming company producing human iPSC-derived cell types at scale, including neural cells for research and drug discovery. Comparable technology platform and pharma customer overlap.
  • Axol Bioscience: Supplier of iPSC-derived neural and other cell types plus custom services for neuroscience and drug discovery research. Direct competitor in iPSC-derived neural cell products.
  • Aspen Neuroscience: Develops autologous iPSC-derived dopaminergic neuron cell therapies for Parkinson's disease. Direct peer to BrainXell's BXT-110 program, using overlapping iPSC-to-dopaminergic-neuron differentiation IP.
  • REPROCELL: Provides iPSC-derived cell products and stem cell-related services for drug discovery and regenerative medicine. Comparable catalog-plus-services model in human iPSC reagents.

Broad incumbents

  • STEMCELL Technologies: Major life sciences tools supplier of stem cell culture reagents, media, and primary cell products. Overlaps with BrainXell via shared stem cell and neural cell research customer base, though STEMCELL has a much broader, less specialized portfolio.
  • Thermo Fisher Scientific: Diversified life sciences tools giant whose bioscience offerings (including Gibco media and cell culture reagents) compete for the same pharma and academic neuroscience budgets. Not a direct neural-cell competitor but competes for tooling wallet.

Emerging players

  • iXCells Biotechnologies: Provider of primary cells, iPSC-derived cells, and custom cell services for drug discovery. Smaller, emerging competitor with overlapping custom services and disease-model offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

BrainXell social profiles

Digital presence

BrainXell financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BrainXell leadership team

Management profile

Number of profiles

Profiles3 records

BrainXell funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BrainXell M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BrainXell

What does BrainXell do?

BrainXell manufactures and sells high-purity, cryopreserved human induced pluripotent stem cell (iPSC)-derived neurons, astrocytes, microglia, endothelial cells, and oligodendrocyte progenitor cells for neuroscience research and drug discovery. The company also offers custom differentiation services (scales from 25 million to 20 billion cells), mRNA-based iPSC reprogramming services, and small-scale assay services (MEA, qPCR, immunofluorescence, toxicity), complemented by BrainFast maturation supplements and BrainBloX modular CNS model systems.

Is BrainXell a public or private company?

BrainXell is a private company. It is classified as venture growth investor backed and is currently operating.

When was BrainXell founded?

BrainXell was founded in 2015. It employs 11 to 50 people.

Where is BrainXell based?

BrainXell is headquartered in Madison, United States, in the North America region.

How does BrainXell make money?

Four revenue lines are on record. iPSC-Derived Cell Products are the primary driver. The others are custom Differentiation Services, iPSC Reprogramming Services and assay Services.

Who are BrainXell's main competitors?

Direct peers on record are NeuCyte, FUJIFILM Cellular Dynamics, Ncardia, bit.bio, Axol Bioscience, Aspen Neuroscience and REPROCELL. Broad incumbents are STEMCELL Technologies and Thermo Fisher Scientific. iXCells Biotechnologies is listed as an emerging player.

Does BrainXell have an API?

No public API is recorded for BrainXell.

What industry is BrainXell in?

BrainXell's product category is iPSC-Derived Neural Cells. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AijournCureC9 and BrainXell Partner to Advance ALS and FTD Research Through Patient-Driven InnovationCureC9 has partnered with BrainXell, Inc. to expand access to patient-derived human iPSC models for C9orf72-associated ALS and FTD research. As part of the collaboration, CureC9 co-founder Yentli Soto Albrecht and her late father have donated skin cells to establish the first patient-derived cell lines in a growing C9orf72 biorepository. These cells will be reprogrammed into iPSCs and differentiated into disease-relevant CNS cell types to provide researchers with standardized, commercially available models for studying neurodegenerative diseases.MorningstarCureC9 and BrainXell Partner to Advance ALS and FTD Research Through Patient-Driven InnovationCureC9 and BrainXell partnered to expand access to patient-derived iPSC models for C9orf72-associated ALS and FTD research. Yentli Soto Albrecht and her late father donated skin cells to establish the first patient-derived cell lines in a growing biorepository. The collaboration aims to provide standardized, commercially available models for researchers.MadisonstartupsBrainXell Launches iPSC-Derived Sensory Neurons - Startup and Tech News - Madison StartupsBiotech company BrainXell has launched its human induced pluripotent stem cell (iPSC)-derived sensory neurons as a scalable cellular platform for research in pain biology, sensory transduction, and ion channel pharmacology. The product is engineered to deliver reproducible functional studies with strong molecular identity and functional responsiveness for researchers in pharmacology and translational neuroscience. BrainXell will showcase the newly launched product in an April 2 presentation on Scientist.com.PR NewswireBrainXell Launches Human iPSC-Derived Sensory Neurons for Translational Neuroscience and Pain Biology ResearchBiotechnology company BrainXell announced on March 4, 2026 the launch of its human iPSC-derived sensory neurons, a scalable cellular platform designed for pain biology, sensory transduction, and ion channel pharmacology research. The platform demonstrates robust expression of key sensory neuron markers including voltage-gated sodium channels (NaV1.7, NaV1.8, NaV1.9), TRP channels, and opioid receptors, with validated lot-to-lot consistency supporting reproducible experimental outcomes. BrainXell researchers will present characterization and functional performance data during a featured presentation on Scientist.com on April 2.MorningstarBrainXell Launches Human iPSC-Derived Sensory Neurons for Translational Neuroscience and Pain Biology ResearchBrainXell announced the launch of its human iPSC-derived sensory neurons, a scalable cellular platform engineered for reproducible functional studies in pain biology, sensory transduction, and ion channel pharmacology. The platform demonstrates robust expression of key sensory neuron markers including Nav1.7, Nav1.8, and Nav1.9 channels, TRP channels, and opioid receptors, with sustained protein expression confirmed through four weeks in culture. The company will present characterization and functional performance data during a featured presentation on April 2 on Scientist.com.PR NewswireBrainXell Showcases Pioneering iPSC Research and Promising In Vivo Data for BXT-110 for Parkinson's Disease at the 2025 Society for Neuroscience Annual MeetingBrainXell, Inc. presented data for its BXT-110 autologous iPSC-derived midbrain dopaminergic progenitor therapy for Parkinson's disease at the 2025 Society for Neuroscience Annual Meeting in San Diego, reporting more than 75 percent FOXA2+/OTX2+ expression, over 60 percent TH+ neurons in vitro, and greater than 60 percent graft survival in vivo. The therapy demonstrated significant behavioral recovery in rodent models within 12 weeks post-transplantation, supporting its candidacy as a disease-modifying treatment for Parkinson's disease. In addition to BXT-110, BrainXell showcased several other research advances including a 3D neurovascular microfluidic model of the human blood-brain barrier and an accelerated differentiation protocol for hiPSC-derived oligodendrocyte progenitor cells reaching more than 95 percent O4+ purity.PR NewswireBrainXell Therapeutics Unveils Promising Preclinical Data Demonstrating Efficacy of BXT-110, an Autologous iPSC-Derived Neuronal Therapy, in Parkinson's DiseaseBrainXell Therapeutics announced preclinical data for BXT-110, an autologous iPSC-derived neuronal therapy for Parkinson's disease, with results to be presented at the Cell Symposia and Society for Neuroscience Annual Meetings. In vivo studies in a 6-OHDA rodent model demonstrated significant graft survival and functional recovery as early as 12 weeks, sustained for up to six months post-transplantation. The company is advancing BXT-110 toward IND-enabling studies as a potential disease-modifying treatment for Parkinson's disease, the second most common neurodegenerative disorder.BioSpaceBrainXell Therapeutics Unveils Promising Preclinical Data Demonstrating Efficacy of BXT-110, an Autologous iPSC-Derived Neuronal Therapy, in Parkinson’s DiseaseBrainXell Therapeutics announced preclinical data for BXT-110, an autologous iPSC-derived neuronal therapy for Parkinson's disease, demonstrating significant graft survival and functional recovery in rodent models. In vivo studies showed efficacy as early as 12 weeks post-transplantation and sustained for up to six months, supporting the therapy's advancement toward IND-enabling studies. The company, a San Diego-based biotechnology firm, will present findings at the Cell Symposia and Society for Neuroscience Annual Meeting this month.